Skip to main content

Table 4 Association of phenotypic changes on T cells with clinical outcome (Relapse vs. NED) (Table 4a) and irAE (Yes vs. No) (Table 4b) was based on univariable logistic regression modeling

From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Biomarker n Slope p-value ½ IQR OR (95% CI)
a. Association of changes in biomarkers at 6 months with outcome (Relapse vs. NED)
%-Ki67 + EOMES + CD4+ 19 −3.5232 0.0285 0.5 0.17 ( 0.04, 0.83)
%-CCR7 + CD8+ 37 −0.0947 0.0379 7.4 0.50 ( 0.26 0.96)
%-EOMES + CD8+ 36 0.1758 0.0072 5.5 2.63 ( 1.30, 5.32)
% EOMES + GranzymeB + CD8+ 19 0.2774 0.0293 5.8 5.00 ( 1.18, 21.23)
b. Association of changes in biomarkers at 6 months with irAE (Yes vs. No)
%-Ki67 + CD8+ 36 −0.3167 0.0217 2.4 0.47 ( 0.24, 0.89)
  1. A total of 37 paired specimens of PBMC prior to and after four doses of ipilimumab were analyzed by flow cytometry for the indicated markers. CCR7 was stained extracellularly, EOMES, granzyme B and Ki67 were stained intracellularly per Materials and Methods.